← Back to all signals
RESEARCH PAPER ANALYSIS

The Impact on Systematic Reviews of Risk of Bias Assessment Changes From Conference Abstracts to Full Text.

This study compared Cochrane risk-of-bias ratings assigned to conference abstracts versus subsequent full-text reports across 52 RCTs and found many abstracts were rated 'unclear' and that full texts more often led to higher or lower risk judgments—notably increased odds of higher risk for…

PMID41982821
JournalCochrane evidence synthesis and methods
Publication Date2026-05-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This study compared Cochrane risk-of-bias ratings assigned to conference abstracts versus subsequent full-text reports across 52 RCTs and found many abstracts were rated 'unclear' and that full texts more often led to higher or lower risk judgments—notably increased odds of higher risk for…

WHY IT MATTERS

Research significance

For Parkinson's therapeutic research, reliance on conference abstracts can mischaracterize trial quality and certainty of evidence, potentially skewing interpretation of intervention efficacy and priorities for follow-up studies or drug development.

ABSTRACT

Source abstract

Conference abstracts are commonly included in systematic reviews of evidence. Due to limitations in word count, conference abstracts often lack data or information. This causes issues for the assessment of risk of bias (RoB). We therefore aimed to compare the RoB rating, using the Cochrane RoB tool, for abstracts and full texts. This was accomplished using previously published Cochrane reviews and comparing RoB ratings for included studies originally included as an abstract and later as full text. To accomplish this, we searched the Cochrane Database of Systematic Reviews for reviews with updates across numerous disciplines (depression, anxiety, surgical, Parkinson's disease, Alzheimer's disease, multiple sclerosis, motor neuron disease, cancer, cardiovascular disease, and musculoskeletal disease). We identified 29 reviews, with 52 randomized controlled trials included, which had an abstract and subsequent full text available. If abstracts and full texts were not assessed using the Cochrane RoB tool, we obtained the texts and performed the assessment (n = 32). To assess the likelihood of changing the domain assessment rating (low, unclear, or high) from conference abstract to full text, we performed a Bayesian categorical multinomial model for each domain (i.e., signaling question) of the Cochrane tool. At the abstract assessment stage, the most common decision was unclear. Using unclear as the reference level in the model led to increased odds of being rated high at full text, compared to abstract assessment, for domains 2 (allocation concealment: odds ratio [OR] = 3.09, 95% credible intervals (CrI) 1.01 to 9.84) and 3 (blinding: OR = 5.09, 95% CrI 1.67 to 16.20). Domain 2 also had odds of being rated low (OR: 2.93, 95% CrI: 1.13 to 7.87). This suggests an impact of changing conference abstract to full text assessments on RoB. The numerous unclear ratings observed at the abstract assessment were usually due to a lack of reporting. While the findings of this study should be interpreted within the context of small numbers, the evidence still suggests that, in some instances, such as allocation concealment and blinding, it is likely that the decision could change based on full-text assessment. This also has implications for the certainty of the evidence, which is impacted by the RoB assessments, with having abstracts only or full texts available potentially changing the overall certainty. Current RoB tools may not be suitable for assessing conference abstracts.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic